Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 32, Issue 1, Pages 8-15Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2010.10.003
Keywords
-
Categories
Funding
- MRC [G1000474, G7811974] Funding Source: UKRI
- National Institute for Health Research [NF-SI-0507-10337, ACF-2007-21-023] Funding Source: researchfish
- Medical Research Council [G7811974, G1000474] Funding Source: Medline
Ask authors/readers for more resources
Bariatric surgery has proven to be an effective means of treating 'diabesity': the combination of type 2 diabetes mellitus (T2DM) and obesity. The effects of surgery go beyond weight loss but reflect a complex alteration in secretion of gut hormones. Finding a pharmaceutical alternative that mimics the benefits of surgery without surgical complications has become the 'holy grail' of the twenty-first century. As knowledge of the multifaceted functions of gut hormones increases, a multitude of drugs that exploit these actions has emerged. In this review, we examine the current understanding of the mechanisms by which bariatric surgery improves diabesity. We also discuss the rapidly emerging role of glucagon-like peptide-1-based treatments as well as the potential for new therapeutics based on other gut hormones (e.g. oxyntomodulin, peptide YY, gastric inhibitory peptide, ghrelin).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available